NICE recommends dabigatran as an option in thromboembolism

NICE has recommended that dabigatran etexilate (Pradaxa) should be considered as a possible treatment for adults with deep vein thrombosis (DVT) or pulmonary embolism (PE).

by
Dabigatran etexilate is rapidly absorbed and converted to its active form dabigatran, which inhibits both free and clot-bound thrombin
Dabigatran etexilate is rapidly absorbed and converted to its active form dabigatran, which inhibits both free and clot-bound thrombin

To continue enjoying this article, please sign in. You can register for free for limited further access, or subscribe now for full access to all our content.

Sign In

Trouble signing in?

Reset password: Click here

Need help? Email us

Register

FREE

  • Limited free articles a month 
  • Free email bulletins

Register Now

Subscribe now

Benefits include:

  • Full site access
  • Subscriber exclusive content
  • Exclusive bulletins

Choose a package